SCHEDULE: FMR LLC Boosts Stake in Stoke Therapeutics
Beneficial Ownership Report
FMR LLC and Abigail P. Johnson report a 13.6% beneficial ownership stake in Stoke Therapeutics Inc., signaling a significant institutional investment.
Summary
- FMR LLC and Abigail P. Johnson collectively hold beneficial ownership of 7,412,982 shares of Stoke Therapeutics Inc. common stock.
- This represents 13.6% of the total outstanding common stock of Stoke Therapeutics Inc.
- FMR LLC, a parent holding company, has sole voting power over 7,405,833 shares and sole dispositive power over 7,412,982 shares.
- Abigail P. Johnson, as an individual, has sole dispositive power over 7,412,982 shares.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Fidelity Management & Research Company LLC, a subsidiary of FMR LLC, beneficially owns 5% or more of the outstanding shares.
Sentiment
Score: 8
Explanation: The disclosure of a significant beneficial ownership stake by a major institutional investor like FMR LLC (Fidelity) and its CEO, Abigail P. Johnson, is a strong positive signal for the company. It indicates substantial institutional confidence and can attract further investor interest.
Positives
- A major institutional investor, FMR LLC (Fidelity), holds a significant 13.6% stake, indicating confidence in Stoke Therapeutics Inc.
- The investment is stated to be in the ordinary course of business, suggesting a long-term investment perspective rather than an activist one.
Negatives
- No specific negative information is disclosed in this ownership filing.
Risks
- No specific risks related to the issuer's operations or financial health are disclosed in this ownership filing, which focuses solely on beneficial ownership.
Future Outlook
NA
Industry Context
This filing indicates a significant investment by a major asset manager (Fidelity) in a biotechnology company, Stoke Therapeutics. Such investments can signal institutional confidence in the company's pipeline or market position within the biotech sector.
Stakeholder Impact
- Shareholders: Existing shareholders may view this as a positive sign of institutional confidence, potentially leading to increased demand and share price appreciation.
- Potential Investors: The significant stake by FMR LLC could attract new investors who follow major institutional investment trends.
Key Dates
| Date | Description |
|---|---|
| 05/23/2023 | Effective date of Power of Attorney for Richard Bourgelas. |
| 08/08/2023 | Date of previous Schedule 13G filing by FMR LLC (accession number -23-002397) where Power of Attorney was incorporated by reference. |
| 06/30/2025 | Date of event which requires filing of this statement (ownership threshold met or changed). |
| 08/05/2025 | Date of filing and signature by FMR LLC and Abigail P. Johnson. |
Recommendation
buyThe disclosure of a substantial 13.6% beneficial ownership by FMR LLC and Abigail P. Johnson, a leading institutional investor, signals strong conviction in Stoke Therapeutics Inc. This significant institutional backing often precedes positive market sentiment and can be a catalyst for share price appreciation, making it a compelling 'buy' signal for investors.
Keywords
Stoke Therapeutics, FMR LLC, Abigail P. Johnson, Institutional Ownership, SEC Filing, Schedule 13G, Biotechnology Investment, Common Stock, Fidelity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.